Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 22, 2026.

Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update

Liping Liu, Zixiao Li, Hongyu Zhou and 16 more

Stroke and Vascular Neurology · 2023

doi:10.1136/svn-2023-002998

Abstract

Background. China is one of the countries with the highest burden of stroke. Implementing multidimensional management guidelines will help clinicians practise evidence-based care, improve patient outcomes and alleviate societal burdens. This update of the 2019 edition will provide the latest comprehensive recommendations for the diagnosis and treatment of ischaemic cerebrovascular diseases.

Methods. We conducted a comprehensive search on MEDLINE (via PubMed) up to 31 August 2023. The writing team established the recommendations through multiple rounds of online and offline discussions. Each recommendation was graded using the evidence grading algorithm developed by the Chinese Stroke Association (CSA). The draft was reviewed and finalised by the CSA Stroke Guidelines Writing Committee.

Results. This update included revisions of 15 existing recommendations and 136 new recommendations in the following areas of stroke care: emergency assessment and diagnosis of ischaemic cerebrovascular disease, acute-phase reperfusion therapy, evaluation of underlying mechanisms, antithrombotic therapy, prevention and treatment of complications, and risk factor management.

Conclusions. This guideline updated the recommendations for the clinical management of ischaemic cerebrovascular disease from 2019.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 22, 2026. Paragraph numbers are ours, so an answer can point at one.

Highlights

The clinical management of ischaemic cerebrovascular diseases comprises a total of 287 recommendations, including 136 new recommendations and 15 revised recommendations from the version in 2019. These highlights reflect significant new therapeutic options developed in recent times that will impact the daily management of patients with acute ischaemic stroke (AIS).

Reperfusion therapy

Tenecteplase (TNK) 0.25 mg/kg intravenous push has been proven non-inferior to intravenous standard dosage of recombinant tissue plasminogen activator (rt-PA) to treat patients with AIS with <4.5 hours of onset (Section 3.1).

For patients with anterior circulation large vessel occlusion (LVO) type of AIS who present within 4.5 hours of symptom onset, the efficacy of intravenous TNK (0.25 mg/kg) is non-inferior to intravenous rt-PA (0.9 mg/kg) before intra-arterial (IA) mechanical thrombectomy (MT). The TNK might offer better reperfusion outcomes, while the incidence of symptomatic intracerebral haemorrhage (sICH) remains similar (Section 3.1).

For patients with AIS with anterior circulation LVO and a large core infarct within 24 hours of onset and who meet the inclusion criteria of the RESCUE-Japan LIMIT, ANGEL-ASPECT and SELECT 2 trials, IA MT is recommended (Section 3.2).

For patients with acute basilar artery occlusion (BAO) within 6 hours of onset who meet the inclusion criteria of the ATTENTION trial, IA MT is recommended (Section 3.2).

Patients with acute BAO within 6–12 hours of onset are recommended for IA MT when they meet the inclusion criteria of the ATTENTION or BAOCHE trials (Section 3.2).

Patients with acute BAO within 12–24 hours of onset are recommended for MT when they meet the inclusion criteria of the BAOCHE trial (Section 3.2).

Antiplatelet therapy

Intravenous tirofiban can be beneficial in those patients who meet the RESCUE BT2 trial inclusion criteria (Section 4.1).

For patients with non-cardioembolic minor ischaemic stroke (IS) (National Institutes of Health Stroke Scale (NIHSS) score ≤3) or high-risk transient ischaemic attack (TIA) (ABCD2 score ≤4) who present within 24 hours of symptom onset, if CYP2C19 gene testing can be tested and the patient carries CYP2C19 loss-of-function (LoF) alleles, ticagrelor plus aspirin for 21 days (ticagrelor loading dose of 180 mg on the first day, followed by 90 mg two times per day) and continue with ticagrelor monotherapy (90 mg two times per day) for 90 days are recommended (Section 4.2).

For patients with moderate IS (NIHSS score of 4–5) who present within 24 hours of symptom onset, ticagrelor plus aspirin for 30 days (ticagrelor loading dose of 180 mg on the first day, followed by 90 mg two times per day) may reduce the risk of recurrent stroke and death within 30 days (Section 4.2).

Brain cytoprotection

Brain cytoprotection with edaravone dexborneol (intravenous 37.5 mg/dose, once every 12 hours, for 14 days) may improve clinical outcomes in patients with AIS (Section 5.1).

DL-3-n-butylphthalide (NBP), 25 mg, dissolved in 100 mL sodium chloride and given as intravenous injection two times per day for the first 14 days, followed by soft 0.2 g capsules of NBP three times a day for the next 76 days, may serve as an adjunct treatment to reperfusion therapy and have the potential to improve functional outcomes in patients with AIS (Section 5.1).

Risk factor management

For patients who cannot tolerate statins or have contraindications to statin therapy, the use of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors or ezetimibe may be considered (Section 9.2).

For patients with IS or TIA with fasting triglycerides (TG) ≥135 mg/dL (1.52 mmol/L), who have received moderate or high-intensity statin therapy, a glycated haemoglobin (HbA1c) level <10%, and no history of pancreatitis, atrial fibrillation, or severe heart failure, treatment with icosapent ethyl (2 g two times per day) can reduce the risk of stroke recurrence (Section 9.2).

Introduction

The incidence of stroke in the Chinese population continues to rise, accounting for nearly one-fourth of the global annual stroke cases. Among adults aged 40 years or above in China, IS accounted for approximately 86.8% of all strokes. Timely updates to the guidelines can provide new evidence-based recommendations for diagnosis, acute-phase treatment, prevention and management of complications, and secondary prevention for IS.

Since the publication of the 2019 Chinese Stroke Association (CSA) guidelines, notable advancements have emerged in acute-phase reperfusion therapy and antiplatelet treatments for secondary IS prevention. The findings of several high-quality randomised controlled trials (RCTs) conducted in China will have an impact on stroke care. Some new lipid-lowering agents are also helpful in stroke prevention.

We conducted a comprehensive search of MEDLINE (via PubMed) up to 31 August 2023, and compiled the relevant information into a tabular format. The writing team established the level of recommendation through multiple rounds of online and offline discussions. Each recommendation was graded using the evidence grading algorithm developed by the CSA (table 1). The updated guideline kept the nine sections: definitions, emergency assessment and diagnosis, reperfusion therapy, antiplatelet therapy, other treatments in the acute phase, general supportive treatment and management of complications, early evaluation of the aetiology and pathogenesis, interventions targeting aetiology and pathogenesis, risk factor management and long-term intervention.

Section 1: definitions associated with ischaemic cerebrovascular diseases

The definitions associated with ischaemic cerebrovascular diseases are shown in table 2.

Section 2: emergency assessment and diagnosis of patients with AIS

The acute care process for patients with AIS is shown in figure 1. The emergency diagnostic and examination process flow chart for patients with AIS is shown in figure 2.

Section 3: reperfusion therapy for AIS

The management process of intravenous thrombolysis for patients with AIS within 4.5 hours of symptom onset is shown in figure 3. The management process of intravenous thrombolysis for patients with AIS with an onset between 4.5 and 9 hours or wake-up stroke is shown in figure 4. The flow chart for IA MT in patients with AIS is shown in figure 5.

Section 4: antiplatelet therapy for acute ischaemic cerebrovascular disease

The antiplatelet treatment process for patients with AIS is shown in figure 6.

Section 6: general supportive treatment and management of complications

The management process for brain oedema/intracranial hypertension is shown in figure 7. The management process for haemorrhagic transformation in patients with AIS is shown in figure 8. The management process for the first seizure within 24 hours of stroke onset is shown in figure 9.

Section 7: early evaluation of aetiology and pathogenesis of ischaemic cerebrovascular disease

The diagnostic process for cryptogenic stroke is shown in figure 10.

Section 8: interventions targeting aetiology and pathogenesis

The treatment strategy for valvular heart disease is shown in figure 11.

Section 9: risk factor management and long-term intervention

The flow chart for blood pressure management within 72 hours after the onset of AIS is shown in figure 12. The flow chart for lipid-lowering management in patients with AIS is shown in figure 13. The flow chart for blood glucose management in patients with AIS is shown in figure 14.

References 290

  1. 1.
    Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 · 2021
    No notice
  2. 2.
    Estimated Burden of Stroke in China in 2020 · 2023
    No notice
  3. 3.

    Li Z, Jiang Y, Li H, et al. China’s response to the rising stroke burden. BMJ 2019;364:l879.

    Not in our library10.1136/bmj.l879

  4. 4.

    Tao C, Nogueira RG, Zhu Y, et al. Trial of endovascular treatment of acute basilar-artery occlusion. N Engl J Med 2022;387:1361–72.

    Not in our library10.1056/nejmoa2206317

  5. 5.

    Jovin TG, Li C, Wu L, et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion. N Engl J Med 2022;387:1373–84.

    Not in our library10.1056/nejmoa2207576

  6. 6.

    Wang Y, Meng X, Wang A, et al. Ticagrelor versus Clopidogrel in cyp2C19 loss-of-function carriers with stroke or Tia. N Engl J Med 2021;385:2520–30.

    Not in our library10.1056/nejmoa2111749

  7. 7.

    Gerschenfeld G, Liegey J-S, Laborne F-X, et al. Treatment times, functional outcome, and hemorrhage rates after switching to tenecteplase for stroke thrombolysis: insights from the Tetris Registry. Eur Stroke J 2022;7:358–64.

    Not in our library10.1177/23969873221113729

  8. 8.

    Lees KR, Emberson J, Blackwell L, et al. Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials. Stroke 2016;47:2373–9.

    Not in our library10.1161/strokeaha.116.013644

  9. 9.

    Campbell BCV, Ma H, Parsons MW, et al. Association of reperfusion after thrombolysis with clinical outcome across the 4.5- to 9-hours and wake-up stroke time window: a meta-analysis of the extend and epithet randomized clinical trials. JAMA Neurol 2021;78:236–40.

    Not in our library10.1001/jamaneurol.2020.4123

  10. 10.

    Goyal M, Almekhlafi M, Dippel DW, et al. Rapid alteplase administration improves functional outcomes in patients with stroke due to large vessel occlusions. Stroke 2019;50:645–51.

    Not in our library10.1161/strokeaha.118.021840

  11. 11.

    Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 2014;311:1632–40.

    Not in our library10.1001/jama.2014.3203

  12. 12.

    Zaidi SF, Shawver J, Espinosa Morales A, et al. Stroke care: initial data from a county-based bypass protocol for patients with acute stroke. J Neurointerv Surg 2017;9:631–5.

    Not in our library10.1136/neurintsurg-2016-012476

  13. 13.

    Patel SC, Levine RS, Tilley BC. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001;286:2830–8.

    Not in our library10.1001/jama.286.22.2830

  14. 14.

    Barber PA, Demchuk AM, Zhang J, et al. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet 2000;355:1670–4.

    Not in our library10.1016/s0140-6736(00)02237-6

  15. 15.

    Kalafut MA, Schriger DL, Saver JL, et al. Detection of early ct signs of >1/3 middle cerebral artery Infarctions: interrater reliability and sensitivity of ct interpretation by physicians involved in acute stroke care. Stroke 2000;31:1667–71.

    Not in our library10.1161/01.str.31.7.1667

  16. 16.

    Larrue V, von Kummer R, del Zoppo G, et al. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European cooperative acute stroke study. Stroke 1997;28:957–60.

    Not in our library10.1161/01.str.28.5.957

  17. 17.

    Thomalla G, Simonsen CZ, Boutitie F, et al. Mri-guided thrombolysis for stroke with unknown time of onset. N Engl J Med 2018;379:611–22.

    Not in our library10.1056/nejmoa1804355

  18. 18.

    Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018;378:11–21.

    Not in our library10.1056/nejmoa1706442

  19. 19.

    Schwamm LH, Wu O, Song SS, et al. Intravenous thrombolysis in unwitnessed stroke onset: Mr witness trial results. Ann Neurol 2018;83:980–93.

    Not in our library10.1002/ana.25235

  20. 20.

    Chalela JA, Kidwell CS, Nentwich LM, et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet 2007;369:293–8.

    Not in our library10.1016/s0140-6736(07)60151-2

  21. 21.

    Kidwell CS, Chalela JA, Saver JL, et al. Comparison of MRI and ct for detection of acute intracerebral hemorrhage. JAMA 2004;292:1823–30.

    Not in our library10.1001/jama.292.15.1823

  22. 22.

    Provost C, Soudant M, Legrand L, et al. Magnetic resonance imaging or computed tomography before treatment in acute ischemic stroke. Stroke 2019;50:659–64.

    Not in our library10.1161/strokeaha.118.023882

  23. 23.

    Menjot de Champfleur N, Saver JL, Goyal M, et al. Efficacy of Stent-retriever Thrombectomy in magnetic resonance imaging versus computed Tomographic perfusion-selected patients in swift prime trial (Solitaire FR with the intention for Thrombectomy as primary Endovascular treatment for acute ischemic stroke). Stroke 2017;48:1560–6.

    Not in our library10.1161/strokeaha.117.016669

  24. 24.

    Krebs S, Posekany A, Pilz A, et al. Ct- versus MRI-based imaging for thrombolysis and mechanical thrombectomy in ischemic stroke: analysis from the Austrian stroke Registry. J Stroke 2022;24:383–9.

    Not in our library10.5853/jos.2021.03846

  25. 25.

    Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 2018;378:708–18.

    Not in our library10.1056/nejmoa1713973

  26. 26.

    Bash S, Villablanca JP, Jahan R, et al. Intracranial vascular stenosis and occlusive disease: evaluation with ct angiography, Mr angiography, and digital subtraction angiography. AJNR Am J Neuroradiol 2005;26:1012–21.

    Not in our library

  27. 27.

    Hirai T, Korogi Y, Ono K, et al. Prospective evaluation of suspected stenoocclusive disease of the intracranial artery: combined Mr angiography and CT angiography compared with Digital subtraction angiography. AJNR Am J Neuroradiol 2002;23:93–101.

    Not in our library

  28. 28.

    Jahan R, Saver JL, Schwamm LH, et al. Association between time to treatment with endovascular reperfusion therapy and outcomes in patients with acute ischemic stroke treated in clinical practice. JAMA 2019;322:252–63.

    Not in our library10.1001/jama.2019.8286

  29. 29.

    Grigoryan M, Haussen DC, Hassan AE, et al. Endovascular treatment of acute ischemic stroke due to tandem occlusions: large multicenter series and systematic review. Cerebrovasc Dis 2016;41:306–12.

    Not in our library10.1159/000444069

  30. 30.

    Olthuis SGH, Pirson FAV, Pinckaers FME, et al. Endovascular treatment versus no Endovascular treatment after 6-24 H in patients with ischaemic stroke and collateral flow on ct angiography (Mr clean-late) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial. Lancet 2023;401:1371–80.

    Not in our library10.1016/s0140-6736(23)00575-5

  31. 31.

    Liebeskind DS, Saber H, Xiang B, et al. Collateral circulation in thrombectomy for stroke after 6 to 24 hours in the dawn trial. Stroke 2022;53:742–8.

    Not in our library10.1161/strokeaha.121.034471

  32. 32.

    Rao VL, Mlynash M, Christensen S, et al. Collateral status contributes to differences between observed and predicted 24-H infarct volumes in defuse 3. J Cereb Blood Flow Metab 2020;40:1966–74.

    Not in our library10.1177/0271678x20918816

  33. 33.

    Tsivgoulis G, Zand R, Katsanos AH, et al. Risk of symptomatic intracerebral hemorrhage after intravenous Thrombolysis in patients with acute ischemic stroke and high cerebral Microbleed burden: a meta-analysis. JAMA Neurol 2016;73:675–83.

    Not in our library10.1001/jamaneurol.2016.0292

  34. 34.

    Zand R, Tsivgoulis G, Singh M, et al. Cerebral microbleeds and risk of intracerebral hemorrhage post intravenous thrombolysis. J Stroke Cerebrovasc Dis 2017;26:538–44.

    Not in our library10.1016/j.jstrokecerebrovasdis.2016.11.127

  35. 35.

    Charidimou A, Turc G, Oppenheim C, et al. Microbleeds, cerebral hemorrhage, and functional outcome after stroke thrombolysis. Stroke 2017;48:2084–90.

    Not in our library10.1161/strokeaha.116.012992

  36. 36.

    Wang S, Lv Y, Zheng X, et al. The impact of cerebral microbleeds on intracerebral hemorrhage and poor functional outcome of acute ischemic stroke patients treated with intravenous thrombolysis: a systematic review and meta-analysis. J Neurol 2017;264:1309–19.

    Not in our library10.1007/s00415-016-8339-1

  37. 37.

    Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–7.

    Not in our library10.1056/nejm199512143332401

  38. 38.

    Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–29.

    Not in our library10.1056/nejmoa0804656

  39. 39.

    Jeong H-G, Kim BJ, Kim T, et al. Classification of cardioembolic stroke based on a deep neural network using chest radiographs. EBioMedicine 2021;69:103466.

    Not in our library10.1016/j.ebiom.2021.103466

  40. 40.

    Tokuda N, Koga M, Ohara T, et al. Urgent detection of acute type a aortic dissection in hyperacute ischemic stroke or transient ischemic attack. J Stroke Cerebrovasc Dis 2018;27:2112–7.

    Not in our library10.1016/j.jstrokecerebrovasdis.2018.03.010

All 290 references

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.